Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Inovio

Wearable Technologies for Detecting Pre-Symptomatic Illness and Infections

Dr. Tejaswini Mishra, Research Scientist at Stanford University School of Medicine, dives into her research on using wearable technologies for detecting COVID-19 and other diseases before patients become symptomatic. Among...

Impetus Digital

- PMLiVE

UK plans to launch new national health agency focused on tackling pandemics

The UK Health Security Agency will protect against future health threats

- PMLiVE

EU, UK working towards a ‘win-win’ situation to expand COVID-19 vaccine supplies

EU leaders are set to meet today to discuss proposed vaccine export plans

- PMLiVE

AZ publishes primary analysis for COVID-19 vaccine, showing slightly lower efficacy of 76%

AZ previously announced vaccine efficacy of 79% in US-based trial

- PMLiVE

Pfizer launches early study of COVID-19 antiviral therapeutic

Therapeutic candidate has demonstrated 'potent' in vivo activity against SARS-CoV-2

- PMLiVE

Efficacy data from US trial for AZ/Oxford vaccine raises concerns over possible ‘incomplete view’

AZ will engage ‘immediately’ with DSMB to share primary analysis with up-to-date efficacy data

- PMLiVE

CureVac expands COVID-19 vaccine trial protocol to include variant specification

Company is aiming to ensure its vaccine efficacy data is 'meaningful' against new virus variants

- PMLiVE

Roche, Regeneron’s COVID-19 antibody cocktail cuts hospitalisation or death by 70%

Phase 3 trial is evaluating the therapy in high-risk non-hospitalised patients with COVID-19

- PMLiVE

EU-UK COVID-19 vaccine row continues as export ban discussion looms

EU officials are set to discuss imposing a vaccine export ban this week

- PMLiVE

AZ/Oxford COVID-19 vaccine hits primary efficacy endpoint in US-based trial

Specific review of thrombotic events found no increased risk of thrombosis associated with vaccine

- PMLiVE

J&J’s MS drug ponesimod receives approval in the US

US regulator has approved the drug – now named Ponvory – for relapsing forms of MS

- PMLiVE

FDA accepts BMS’ investigational cardiovascular drug mavacamten for review

BMS gained the rights to mavacamten as part of its acquisition of MyoKardia

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links